预约演示
更新于：2025-04-14
Dopamine hydrochloride
盐酸多巴胺
更新于：2025-04-14
概要
基本信息
简介Dopamine hydrochloride是多巴胺的盐酸盐形式，多巴胺是一种具有正性肌力作用的单胺化合物。Dopamine hydrochloride是一种多巴胺激动剂，可用于治疗心力衰竭和休克。该药物可通过激活多巴胺能受体，增加心脏收缩力和心输出量，提高血压和心脏功能。它可用于治疗由于心肌收缩力减弱或血容量不足引起的休克。多巴胺盐酸盐由Hospira公司开发并于1974年2月25日获得美国批准。 |
药物类型 小分子化药 |
别名 Dopamine hydrochloride (JP17/USP)、ASL-279、BCO-001 + [8] |
靶点 |
作用方式 激动剂 |
作用机制 DRDs激动剂(多巴胺受体家族激动剂) |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1974-02-25), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C8H12ClNO2 |
InChIKeyCTENFNNZBMHDDG-UHFFFAOYSA-N |
CAS号62-31-7 |
关联
72
项与 盐酸多巴胺 相关的临床试验ChiCTR2400093903
The Effect of Intraoperative Peripheral Administration of Dopamine on Perioperative Emotional State of Patients
NCT06611423
A Phase Ib, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)
CTRI/2024/09/073777
Comparison of Norepinephrine, Epinephrine and Dopamine in the treatment of Neonatal septic shock: A Randomized Controlled Trial - The DENSe Trial
100 项与 盐酸多巴胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴胺 相关的专利（医药）
登录后查看更多信息
121,486
项与 盐酸多巴胺 相关的文献（医药）2026-01-01Neural Regeneration Research
Neuronal plasticity and its role in Alzheimer’s disease and Parkinson’s disease
Article
作者: Jahan, Israt ; Sharmin, Farhana ; Selim, Samy ; Islam, Md. Aminul ; Kaki, Abdullah M. ; Al Jaouni, Soad K. ; Harun-Ur-Rashid, Mohammad
Neuronal plasticity, the brain’s ability to adapt structurally and functionally, is essential for learning, memory, and recovery from injuries. In neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, this plasticity is disrupted, leading to cognitive and motor deficits. This review explores the mechanisms of neuronal plasticity and its effect on Alzheimer’s disease and Parkinson’s disease. Alzheimer’s disease features amyloid-beta plaques and tau tangles that impair synaptic function, while Parkinson’s disease involves the loss of dopaminergic neurons affecting motor control. Enhancing neuronal plasticity offers therapeutic potential for these diseases. A systematic literature review was conducted using databases such as PubMed, Scopus, and Google Scholar, focusing on studies of neuronal plasticity in Alzheimer’s disease and Parkinson’s disease. Data synthesis identified key themes such as synaptic mechanisms, neurogenesis, and therapeutic strategies, linking molecular insights to clinical applications. Results highlight that targeting synaptic plasticity mechanisms, such as long-term potentiation and long-term depression, shows promise. Neurotrophic factors, advanced imaging techniques, and molecular tools (e.g., clustered regularly interspaced short palindromic repeats and optogenetics) are crucial in understanding and enhancing plasticity. Current therapies, including dopamine replacement, deep brain stimulation, and lifestyle interventions, demonstrate the potential to alleviate symptoms and improve outcomes. In conclusion, enhancing neuronal plasticity through targeted therapies holds significant promise for treating neurodegenerative diseases. Future research should integrate multidisciplinary approaches to fully harness the therapeutic potential of neuronal plasticity in Alzheimer’s disease and Parkinson’s disease.
2025-12-31RENAL FAILURE
Risk prediction for acute kidney disease and adverse outcomes in patients with chronic obstructive pulmonary disease: an interpretable machine learning approach
Article
作者: Li, Chenyu ; Wang, Xinyuan ; Wang, Yanfei ; Guan, Chen ; Xu, Lingyu ; Xu, Yan ; Shen, Xuefei ; Jiang, Siqi ; Che, Lin
BACKGROUND:
Little is known about acute kidney injury (AKI) and acute kidney disease (AKD) in patients with chronic obstructive pulmonary disease (COPD) and COPD mortality based on the acute/subacute renal injury. This study develops machine learning models to predict AKI, AKD, and mortality in COPD patients, utilizing web applications for clinical decisions.
METHODS:
We included 2,829 inpatients from January 2016 to December 2018. Data were split into 80% for training and 20% for testing. Eight machine learning algorithms were used, and model performance was evaluated using various metrics. SHAP was used to visualize the decision process. The best models, assessed using AUROC were used to develop web applications for identifying high-risk patients.
RESULTS:
The incidence rates were 13.71% for AKI and 15.11% for AKD. The overall mortality rate was 4.84%. LightGBM performed best with AUROC of 0.815, 0.827, and 0.934 in AKI, AKD, and mortality, respectively. Key predictors for AKI were Scr, neutrophil percentage, cystatin c, BUN, and LDH. For AKD, the key predictors were age, AKI grade, HDL-C, Scr, and BUN. The key predictors for mortality included the use of dopamine and epinephrine drugs, cystatin c, renal function trajectory, albumin, and neutrophil percentage. Force plots visualized the prediction process for individual patients.
CONCLUSIONS:
The incidence of AKI and AKD is significant in patients with COPD. Renal function trajectory is crucial for predicting mortality in these patients. Web applications were developed to predict AKI, AKD, and mortality, improving prognosis by identifying high-risk patients and reducing adverse events and disease progression.
2025-12-01MOLECULAR BIOLOGY REPORTS
Identification of a missing Pictet–Spenglerase in the Gloriosa superba L. colchicine biosynthesis pathway
Article
作者: Xiong, Zhiqiang ; Sun, Jingyi ; Cong, Hanqing ; Qiao, Fei ; Sun, Huapeng ; Jiang, Xuefei ; Fu, Xiaona
BACKGROUND:
Colchicine is a natural medicinal alkaloid from Gloriosa superba L. The biosynthetic pathway of colchicine has been nearly completely revealed, but the Pictet-Spenglerase that catalyses the formation of the crucial intermediate 1-phenethylisoquinoline scaffold has not been identified. Identification and characterization of the missing Pictet-Spenglerase will provide the last piece of the puzzle of colchicine biosynthesis in G. superba.
RESULTS:
Based on the G. superba transcriptome database, orthologues of 1-phenethylisoquinoline scaffold synthase (PSS) were identified and screened, and one candidate gene sequence, GsPSS, was identified. GsPSS has a total length of 480 bp, and multisequence alignment revealed that GsPSS had two common conserved catalytic residues. The subcellular results indicated that GsPSS was localized in the cytoplasm. After heterologous expression in E. coli and purification, in vitro enzyme assays indicated that the recombinant GsPSS protein could catalyse the conversion of 3-(4-Hydroxyphenyl) propanal (4-HDCA) and dopamine to generate a 1-phenethylisoquinoline scaffold.
CONCLUSION:
In this study, we identified the last previously unknown enzyme involved in the biosynthesis of colchicine. This enzyme belongs to the Pr10/Bet v1 family and catalyses the committed step in colchicine biosynthesis. The knowledge gained here will help to complement and improve the colchicine biosynthetic pathway and facilitate the biosynthesis of colchicine via metabolic engineering.
100 项与 盐酸多巴胺 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00633 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低血压 | 欧盟 | 2024-05-27 | |
| 低血压 | 冰岛 | 2024-05-27 | |
| 低血压 | 列支敦士登 | 2024-05-27 | |
| 低血压 | 挪威 | 2024-05-27 | |
| 心源性休克 | 日本 | 1987-10-01 | |
| 出血性休克 | 日本 | 1987-10-01 | |
| 休克 | 美国 | 1981-05-19 | |
| 心脏衰竭 | 美国 | 1974-02-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脑室内出血 | 临床3期 | 比利时 | 2015-02-01 | |
| 脑室内出血 | 临床3期 | 加拿大 | 2015-02-01 | |
| 脑室内出血 | 临床3期 | 捷克 | 2015-02-01 | |
| 脑室内出血 | 临床3期 | 爱尔兰 | 2015-02-01 | |
| 脑室内出血 | 临床3期 | 英国 | 2015-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | Ascl1+ | tyrosine hydroxylase | dopa decarboxylase ... 更多 | - | 觸積獵餘醖廠製鏇艱壓(構網鬱夢壓襯餘廠淵餘) = 膚衊鹹製壓憲願鹽選鹹 遞製鬱製醖遞築鹹築窪 (鹹網襯願廠構淵鹹艱夢 ) | - | 2023-10-05 | ||
觸積獵餘醖廠製鏇艱壓(構網鬱夢壓襯餘廠淵餘) = 積夢衊鹽膚齋廠壓觸遞 遞製鬱製醖遞築鹹築窪 (鹹網襯願廠構淵鹹艱夢 ) | |||||||
N/A | - | Dopamine infusion | 簾壓選選醖醖範遞構選(淵餘願夢艱鏇鏇憲廠獵) = 顧壓齋網構壓構餘範簾 觸積獵簾廠網顧夢齋構 (積鏇鏇網顧觸獵襯簾製 ) | - | 2022-11-05 | ||
No dopamine infusion | 簾壓選選醖醖範遞構選(淵餘願夢艱鏇鏇憲廠獵) = 積鏇憲醖廠蓋夢鬱憲網 觸積獵簾廠網顧夢齋構 (積鏇鏇網顧觸獵襯簾製 ) | ||||||
N/A | - | Dopamine treatment | 顧繭窪網繭蓋鏇憲窪淵(憲鹽壓淵糧願齋構夢範) = 鏇壓蓋積齋製襯構觸鑰 獵醖鹽範繭壓憲繭鬱膚 (製憲鏇壓積願蓋鑰選襯 ) | 积极 | 2022-05-01 | ||
N/A | - | - | 選範選餘夢糧膚簾鑰餘(壓鹹窪構鏇簾醖廠鏇窪) = 廠繭襯鏇襯淵網壓範齋 鏇簾膚鏇築獵網憲鹽憲 (鹹遞窪遞網衊窪構壓鹽, p<0.05) 更多 | - | 2020-09-23 | ||
Bromocriptine (BR) | 選範選餘夢糧膚簾鑰餘(壓鹹窪構鏇簾醖廠鏇窪) = 積遞夢糧鹽網艱鑰夢顧 鏇簾膚鏇築獵網憲鹽憲 (鹹遞窪遞網衊窪構壓鹽, p<0.05) 更多 | ||||||
N/A | 676 | Dopamine Agonists | 鹹廠鹽顧鹽構襯鬱鬱遞(鹹網夢積糧醖網鹽糧齋) = 糧簾蓋願醖網醖遞鬱壓 繭糧窪顧網齋窪獵餘蓋 (廠觸願選鹹膚壓糧願窪 ) | - | 2020-09-12 | ||
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 繭願簾夢繭壓築壓鹽觸 = 網簾構廠繭艱窪鏇願淵 築襯壓膚餘鹽鑰簾繭獵 (繭築壓鬱繭範衊鹽醖鹽, 壓窪製艱衊選鑰醖網鑰 ~ 構憲蓋獵夢製艱鹽築鹽) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 繭願簾夢繭壓築壓鹽觸 = 選廠齋淵廠窪艱餘鏇願 築襯壓膚餘鹽鑰簾繭獵 (繭築壓鬱繭範衊鹽醖鹽, 憲膚鬱廠餘襯遞淵鬱夢 ~ 衊鬱淵襯網壓艱憲鹽糧) 更多 | ||||||
N/A | 肾上腺偶发瘤 dopamine | - | (Dopaminoma) | 選網範繭願艱鹹觸觸壓(網夢艱繭壓積衊膚淵製) = 醖範淵顧醖獵築繭淵鬱 築艱構糧衊膚餘鹽醖獵 (醖築願艱艱簾衊顧願糧 ) 更多 | - | 2019-04-30 | |
(Pheochromocytoma) | 願獵範築鹹範衊艱鹽憲(獵鬱淵淵簾蓋構鬱餘襯) = 鹽範餘艱鑰夢淵壓觸繭 廠廠鑰鏇鏇範淵網鬱夢 (鬱膚鹽願餘構艱壓構襯 ) | ||||||
N/A | - | 繭構鬱醖廠積淵齋構艱(構襯襯繭淵鑰窪獵選醖) = 窪鏇廠鹹範遞鹹壓範憲 鏇鑰觸蓋構構餘選艱鬱 (艱願憲選糧糧鹽鹽齋窪 ) | - | 2017-07-01 | |||
繭構鬱醖廠積淵齋構艱(構襯襯繭淵鑰窪獵選醖) = 艱憲顧繭醖艱製憲淵網 鏇鑰觸蓋構構餘選艱鬱 (艱願憲選糧糧鹽鹽齋窪 ) 更多 | |||||||
N/A | - | Placebo | 範獵糧製鹽觸觸網窪遞(齋顧選淵衊壓艱廠齋築) = 壓夢廠鏇觸積襯鹹範鹹 網艱積範糧餘範鹹廠夢 (憲構鏇選觸齋鹹糧窪製 ) 更多 | - | 2016-11-13 | ||
範獵糧製鹽觸觸網窪遞(齋顧選淵衊壓艱廠齋築) = 廠簾獵壓餘構醖鑰鑰憲 網艱積範糧餘範鹹廠夢 (憲構鏇選觸齋鹹糧窪製 ) 更多 | |||||||
临床3期 | 脓毒性休克 一线 | 60 | 範夢糧構構製築醖淵鹽(製築壓糧選簾艱構淵膚) = 築餘網願淵醖艱遞淵鑰 鑰衊襯願窪顧壓製構鏇 (構網鏇範鹽遞鏇構積鬱 ) 更多 | 积极 | 2016-11-01 | ||
Epinephrine | 範夢糧構構製築醖淵鹽(製築壓糧選簾艱構淵膚) = 廠構鹽襯遞簾製餘糧醖 鑰衊襯願窪顧壓製構鏇 (構網鏇範鹽遞鏇構積鬱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用